October 14, 2014

PALO ALTO, CA–(Marketwired – Oct 13, 2014) – FLG Partners  today announced the election of Mark Murray as a partner in the firm, bringing the number of partners to 24.

“We are very pleased that Mark has joined the firm,” said Jeffrey Kuhn, Managing Partner of FLG. “Mark has had a distinguished career in a broad scope of health care companies ranging from startups to billion dollar public companies. With his addition FLG continues to build on our position as the leading CFO consulting and Board advisory firm in Silicon Valley and the Western United States.”

“I am thrilled to join the firm,” said Mr. Murray. “FLG is clearly recognized as the premier CFO consultancy and advisory firm in Silicon Valley and across the Western United States, and it is honor for me to work with FLG’s distinguished partners,” Mr. Murray added.

Prior to joining FLG, Mark was Chief Financial Officer of OptiMedica Corporation, a venture-backed ophthalmology company that was successfully acquired by Abbott Labs in 2013. During his time at OptiMedica, Mark oversaw equity & debt financing greater than $90 million, sold part of the business in an asset sale in 2010 for $60 million and grew revenue for OptiMedica’s laser cataract business to nearly $20 million prior to the acquisition of OptiMedica by Abbott Labs for $400 million.

Previously to OptiMedica, Mark was Chief Financial Officer of Emphasys Medical, a ventured back interventional pulmonology company, in which he filed the company’s S-1 initial public offering and raised $15 in debt financing.

Previously, Mark spent 21 years with Guidant Corporation, including its predecessor Advanced Cardiovascular System and its successor Abbott Labs/Boston Scientific. Mark was part of Guidant’s senior management team and participated in its $1 billion IPO through its exit in 2006 for $27 billion by Abbott Labs/Boston Scientific. During those 21 years, Mark led the finance team of Guidant’s Vascular Intervention group overseeing revenue growth from less than $20 million to over $1.3 billion; lead the business development team in strategic transactions that included M&A, drug in-licensing, OEM and equity investments; and oversaw the global installation of SAP.

Mark started his career with international CPA firms of Ernst & Whinney and Main Hurdman.

Mark holds a BS in business administration (in accounting) from California State University, San Francisco.